Exploring the Androgen Deficiency Syndrome After Endocrine Therapy for Prostate Cancer Based on the "Yin-Ping Yang-Mi" Theory
DOI:
https://doi.org/10.71321/xj2h8w39Keywords:
Prostate Cancer, Yin-Yang Balance, Androgen Deficiency SyndromeAbstract
Androgen deficiency syndrome (ADS) is a subsequent condition that arises after endocrine therapy for prostate cancer. It manifests as a reduction in testosterone levels accompanied by symptoms such as soreness and weakness of low back and knees, fatigue, hot flushes, and night sweats. This syndrome represents an imbalance between the opposing and complementary forces of yin and yang within the body. Utilizing the yin-yang theory of traditional Chinese medicine, this study analyzes the dynamic interplay of yin and yang associated with androgen deficiency syndrome after endocrine therapy for prostate cancer. The objective is to provide theoretical guidance from Chinese medicine for addressing androgen deficiency syndrome by restoring “the balance of yin and yang." This research contributes to understanding the potential applications of traditional Chinese medicine in managing hormone-related conditions among prostate cancer patients.
References
[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, & Jemal A, et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71(3):209-249. https://doi.org/10.3322/caac.21660
[2] Lu X, Jiang DM, Hu M, Yang YH, Zhang LJ, & Hou JG, et al. (2021). Mortality analysis and time trend of prostate cancer in China from 2004 to 2008. Shanghai Journal of Preventive Medicine, 33(10):899-904,912. https://doi.org/10.19428/j.cnki.sjpm.2021.21084
[3] Qu M, & Gao X. (2022). Prostate cancer in the world and China in 2022: An epidemiological analysis. Journal of Naval Medical University, 1-6. https://doi.org/10.16781/j.CN31-2187/R.20240685
[4] Al-Ghazawi M, Salameh H, Amo-Afful S, et al. (2023). An in-depth look into the epidemiological and etiological aspects of prostate cancer: a literature review. Cureus, 15(11):e48252. https://doi.org/10.7759/cureus.48252
[5] López, J., Añazco-Guenkova, A. M., Monteagudo-García, Ó., & Blanco, S. (2022). Epigenetic and Epitranscriptomic Control in Prostate Cancer. Genes, 13(2), 378. https://doi.org/10.3390/genes13020378
[6] Li XJ, Feng MH, Mou R, Guo S, Li W, Zhang C. (2020). Research Progress of Chinese Medicine Intervention on Partial Androgen Deficiency Syndrome after Endocrine Therapy of Prostate Cancer. Tianjin Journal of Traditional Chinese Medicine, 37(07), 831-835.
[7] Dudek P, Kozakowski J, & Zgliczynski W. (2017). Late-onset hypogonadism. Przegl Menopauzalny, 16(2):66-69. https://doi.org/10.5114/pm.2017.68595
[8] Coward RM, McBride JA, & Carson CC. (2015). Diagnosis and management of testosterone deficiency. Asian Journal of Andrology. https://doi.org/10.4103/1008-682x.143317
[9] Wang Q, Gao Z, & Wei Y. (2025). Expert consensus on traditional Chinese medicine diagnosis and treatment of complications after androgen deprivation therapy for prostate cancer.Chinese Journal of Experimental Traditional Medical Formulae, (1). https://doi.org/10.13422/j.cnki.syfjx.20250591
[10] Saylor PJ, Keating NL, & Smith MR. (2009). Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. Journal of General Internal Medicine, 24(S2):389-94. https://doi.org/10.1007/s11606-009-0968-y
[11] Cittadini A, Isidori AM, & Salzano A. (2022). Testosterone therapy and cardiovascular diseases. Cardiovascular Research, 118(9):2039-57. https://doi.org/10.1093/cvr/cvab241
[12] Xia JN. (2015). Theoretical research of consumptive disease in TCM [Doctoral dissertation]. Beijing: China Academy of Chinese Medical Sciences.
[13] Wang QZ, Yi G, & Wang B. (2024). Treatment of prostate cancer after androgen deprivation by means of submerge yang and sealing marrow. Asia Pac Tradit Med, 20(2):81-4. https://doi.org/10.11954/ytctyy.202402020
[14] Chinese Association of Sexology Traditional Chinese Medicine Sexology Branch Expert Consensus Writing Group, & Chinese Medical Doctor Association Integrative Medicine Physician Branch Urological Surgery Professional Committee Expert Consensus Writing Group. (2025). Expert consensus on traditional Chinese medicine diagnosis and treatment of complications after androgen deprivation therapy for prostate cancer. Chinese Journal of Experimental Traditional Medical Formulae, 31(1), 193-200. https://doi.org/10.13422/j.cnki.syfjx.20250591
[15] Fu MJ. (2017). Effects of Zhibai Dihuang Pill combined with Polyporus Decoction in treating primary nephrotic syndrome and its influence on inflammatory factors. Modern Journal of Integrated Traditional Chinese and Western Medicine, 26(22):2453-5. https://doi.org/10.3969/j.issn.1008-8849.2017.22.020
[16] Zhang ZD, Bai HD, Zeng YN, Kuang HX, & Wang QH. (2023). Research progress of Anemarrhenae Rhizoma and its couplet medicines. Chinese Archives of Traditional Chinese Medicine, 41(10):98-101. https://doi.org/10.13193/j.issn.1673-7717.2023.10.020
[17] Chen L, Li ZZ, & Xi Q. (2021). Zhibai Dihuang Pills combined with Yougui Capsules in treatment of oligoasthenospermia of kidney deficiency type. Drugs & Clinic, 36(11):2346-50. https://doi.org/10.7501/j.issn.1674-5515.2021.11.025
[18] Liu H, Tang H, & Guo ZC. (2016). Clinical study on Zhibai Dihuang decoction combined with endocrine therapy in treating kidney-yin deficiency type of advanced prostate cancer. Chinese Journal of Information on Traditional Chinese Medicine, 23(4):24-7. https://doi.org/10.3969/j.issn.1005-5304.2016.04.007
[19] Zhu X, Zhang ZM, Gao WX, Xing LB, Hu SW, & Zeng LQ. (2016). Clinical study of traditional Chinese medicine in treatment of androgen deficiency syndrome in prostate cancer patients after androgen deprivation therapy. Hubei Journal of Traditional Chinese Medicine, 38(7):14-5. https://doi.org/10.3969/j.issn.1005-5304.2016.04.007
[20] Zhong DL & Zhang LH. (2024). Opinion on Relative Equilibrium of Yin-yang. Chinese Medicine Modern Distance Education of China, 22(4), 51-53.
[21] Zhu, S. N. (1996). Revisiting that "yin-ping-yang-mi" is not equal to yin-yang balance. Journal of Shandong University of Traditional Chinese Medicine, (2), 74-78.
[22] Chen YP. (2009). On the "homeostasis" theory and the health preservation concept of "yin-yang balance" in traditional Chinese medicine. Mod J Integr Tradit Chin West Med, 18(22), 2638-2640. https://doi.org/10.3969/j.issn.1008-8849.2009.22.009
[23] Shen GY. (2011). My perspective on "yin-ping-yang-mi". J Sichuan Tradit Chin Med, 29(10), 41-43.
[24] Wang QY & Zheng HX. (2019). "Kidney yin and kidney yang disorder" in traditional Chinese medicine and mechanism of intestinal barrier dysfunction. Chin Arch Tradit Chin Med, 37(3), 635-637. https://doi.org/10.13193/j.issn.1673-7717.2019.03.029
[25] Tan CE & Yang F. (2018). Discussion on immune function features of kidney-yang from aspect of associativity between Chinese and Western medicine theories. Chin J Inf Tradit Chin Med, 25(8), 1-3. https://doi.org/10.3969/j.issn.1005-5304.2018.08.001
[26] Li LH & Zhang PQ. (2018). Professor Zhang Qi's experience in treating chronic kidney disease by regulating kidney yin and yang. Chin J Integr Tradit West Nephrol, 19(6), 476-477. https://doi.org/10.3969/j.issn.1009-587X.2018.06.003
[27] Pang K, Zhou ZG, Huang YF, Liu CB & Xu W. (2016). Clinical Efficacy and Safety of Bicalutamide Combined with Goserelin in the Treatment of Advanced Prostate Cancer. Chin J Clin Pharmacol, 32(3), 224-226. https://doi.org/10.13699/j.cnki.1001-6821.2016.03.010
[28] Wang QZ, Yi G, Wang B, et al. (2024). Treatment of Prostate Cancer After Androgen Deprivation by Means of Submerge Yang and Sealing Marrow. Asia-Pac Tradit Med, 20(2), 81-84. https://doi.org/10.11954/ytctyy.202402020
[29] Chen JF, Lin PW, Tsai YR, Yang YC & Kang HY. (2019). Androgens and androgen receptor actions on bone health and disease: From androgen deficiency to androgen therapy. Cells, 8(11), 1318. https://doi.org/10.3390/cells8111318
[30] Romejko K, Rymarz A, Sadownik H, & Niemczyk S. (2022). Testosterone deficiency as one of the major endocrine disorders in chronic kidney disease. Nutrients, 14(16), 3438. https://doi.org/10.3390/nu14163438
[31] Ros CT, Ros LU, & Ros JPU. (2022). The role of clomiphene citrate in late onset male hypogonadism. Int Braz J Urol, 48(3), 456-465. https://doi.org/10.1590/s1677-5538.ibju.2021.0724
[32] Lou YJ, Wang J & Huang YQ. (2018). Improvement effects of Morinda officinalis and its processed products on HPA axis function in kidney-yang deficiency rats. Chin Tradit Pat Med, 40(11), 2535-2539. https://doi.org/10.3969/j.issn.1001-1528.2018.11.033
[33] Xiao ZZ, Yang ML, Dai B, Zhang JN, Shi JL, Xiao WZ, et al. (2016). Effects of Liuwei Dihuang decoction and "reinforcing and reducing" couplet medicines on HPA axis and morphologic changes of the adrenal cortex in kidney yin deficiency mice. J Hunan Univ Chin Med, 36(3), 17-20. https://doi.org/10.3969/j.issn.1674-070X.2016.03.005
[34] Zhang LN, Chen DX, Wang QP, Peng ZL, & Liu YJ. (2024). Research progress in the pharmacological actions and mechanism of kidney-supplementing prescriptions for the treatment of male reproductive function decline caused by kidney deficiency. Guangzhou Zhongyiyao Daxue Xuebao, 41(9):2499-2508. https://doi.org/10.13359/j.cnki.gzxbtcm.2024.09.040
[35] Chen SK, & Lu Y. (2023). Discussion on the treatment of male climacteric syndrome from kidney. J Pract Tradit Chin Intern Med, 37(6), 103-105. https://doi.org/10.13729/j.issn.1671-7813.Z20220238
[36] Xiong TY, Zhao YQ, Xie P, & Niu YN. (2025). Research progress on interaction mechanism between androgen receptor and PI3K/AKT pathway in prostate cancer. J Cap Med Univ, 46(2), 269-282.
[37] Niu YJ, Yu JP, & Wang KR. (2025). Research progress in immunotherapy for prostate cancer. J Mod Urol, 1-7.
[38] Mandel A, Larsson P, Sarwar M, Semenas J, Syed KAS, & Persson J. (2018). The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer. Mol Med, 24(1), 25. https://doi.org/10.1186/s10020-018-0035-4
[39] Dai C, Heemers H, & Sharifi N. (2017). Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med, 7(9), a030452. https://doi.org/10.1101/cshperspect.a030452
[40] Wang AM, Ma DY, Zhao ZW, Wang H, & Yang JT. (2024). Differentiation and treatment of benign prostatic hyperplasia based on the principle of "if kidney and essence are in deficiency, semen chamber will be in dysfunction". Acta Chin Med Pharmacol, 52(7), 47-51. https://doi.org/10.19664/j.cnki.1002-2392.240136
[41] Xu CL, Liang JQ, Wang JH, Dong HY, Han ZY, Li F, et al. (2023). Overview of clinical research on traditional Chinese medicine ancient prescriptions for prostate cancer. Yunnan J Tradit Chin Med Mater Med, 44(1), 90-94. https://doi.org/10.3969/j.issn.1007-2349.2023.01.023
[42] Chen L, Zhang YY, Zhang WJ, Wang YX & Guo LZ. (2024). Exploration of the Application of the Yang-Nourishing and Yin-Dispersing Method in the Treatment of Breast Nodules Based on the Theory of "Yang Transforming Qi, Yin Forming Substance". Clin J Tradit Chin Med, 1-8.
[43] Guo YL, Na YQ, Ye ZQ, Sun YH, Huang J & Wang JY. (2022). Chinese Guidelines for the Diagnosis and Treatment of Urological and Andrological Diseases (2022 Edition). Beijing: Science Press, 1137.
[44] Cheng HB, Wang JY, & Li L. (2019). Classification of pathogenesis of cancer toxin and application in the clinical treatment of cancer. J Tradit Chin Med, 60(2), 119-122. https://doi.org/10.13288/j.11-2166/r.2019.02.008
[45] Li C, Yao Y, Li L, Wang JY, & Cheng HB. (2024). Syndrome differentiation and treatment of carcinoma of prostate based on the pathogenesis theory of cancer toxin. J Beijing Univ Tradit Chin Med, 47(3), 307-311.
[46] Zhu HM, Liu Q, Li W, Huang SM, Zhang B, & Wang YM. (2022). Biological deciphering of the "kidney governing bones" theory in traditional Chinese medicine. Evid Based Complement Alternat Med, 2022, 1685052. https://doi.org/10.1155/2022/1685052
[47] Liu QX, & Ju BZ. (2025). Exploring the treatment ideas of senile dementia based on the theory of "balance between yin and yang" in Huang Di Nei Jing. Clin J Tradit Chin Med, 37(1), 5-8. https://doi.org/10.16448/j.cjtcm.2025.0102
[48] Zhang XQ, Jia YJ, Wang LH, Mou RY, Guo SQ, Zhang Y, et al. (2022). Clinical Efficacy and Safety of "Invigorating Spleen, Invigorating Dampness and Removing Stasis Method" Combined with Abiraterone Acetate in Treatment of Metastatic Castration-Resistant Prostate Cancer Based on Theory of "Chuzhuo Peiben". Chin Tradit Herb Drugs, 53(20), 6536-6543. https://doi.org/10.7501/j.issn.0253-2670.2022.20.023
[49] Niu XF, Wu MX, Mou RY & Li XJ. (2022). Professor Jia Yingjie's Experience in the Treatment of Prostate Cancer by Using the Theory of "Chuzhuo Peiben". Shaanxi J Tradit Chin Med, 43(1), 111-113+117. https://doi.org/10.3969/j.issn.1000-7369.2022.01.036
[50] Zhu SL & He ZP. (2021). Professor Chen Zhiqiang's Experience in Staging and Syndrome Differentiation for Treating Prostate Cancer. Hebei J Tradit Chin Med, 43(4), 541-544. https://doi.org/10.3969/j.issn.1002-2619.2021.04.001
[51] Jiang SL, & Hua BJ. (2015). Essence of phlegm-stasis leading to the genesis and development of tumor and the dialectical relationship between phlegm-stasis and tumor microenvironment. Zhongguo Zhong Yi Ji Chu Yi Xue Za Zhi, 21(11):1417-1419.
[52] Li WD, & Wang J. (2024). The current state of inflammation-related research in prostate cancer: a bibliometric analysis and systematic review. Front Oncol, 14:1432857. https://doi.org/10.3389/fonc.2024.1432857
[53] Sun RB, Han QR, &Xu M. (2021). Discussion on pathogenesis of deficiency of healthy-qi and stagnation of phlegm & blood in tumor pre-metastatic niche. Zhonghua Zhong Yi Yao Za Zhi, 36(6):3529-3532.
[54] Archer M, Dogra N, & Kyprianou N. (2020). Inflammation as a driver of prostate cancer metastasis and therapeutic resistance. Cancers, 12(10):2984. https://doi.org/10.3390/cancers12102984
[55] Wei YJ, Zheng Q, Zhou HJ, Zhao MY, Ran W, &Tang JY, et al. Discussion on the research progress of traditional Chinese medicine in the prevention and treatment of tumor based on the thought of deficiency of vital Qi. Zhong Yi Yao Lin Chuang Za Zhi. 2023;35(4):655-60. https://doi.org/10.16448/j.cjtcm.2023.0408
[56] Jiang YQ, Wu GZ & Wang W. (2015). Retrospective study on the efficacy of surgical castration versus medical castration in prostate cancer treatment. Hebei Med J, 21, 3234-3236. https://doi.org/10.3969/j.issn.1002-7386.2015.21.010
[57] Wang QX, Lu WJ, Meng H, Dong JT, Liu YZ, & Li C, et al. (2020). Mechanisms of male erectile dysfunction and advances in traditional Chinese medicine prevention and treatment. Zhongguo Zhong Yi Ji Chu Yi Xue Za Zhi, 26(10):1578-1581. https://doi.org/10.3969/j.issn.1006-3250.2020.10.048
[58] Dai M, Liu J & Sheng ZY. (2021). A review and analysis of Chinese medical practitioners' understanding of consumptive disease throughout history. Glob Tradit Chin Med, 14(4), 627-630. https://doi.org/10.3969/j.issn.1674-1749.2021.04.008
[59] Ning G, Wu H, & Zhou X. (2022). Analysis of correlation between Tiangui and testosterone. Hunan Zhong Yi Yao Da Xue Xue Bao, 42(1):73-77. https://doi.org/10.3969/j.issn.1674-070X.2022.01.014
[60] Zeng YL, Zhu HQ, & Xu XL. (2020). Discussion on TCM "Tiangui" and its pathological mechanism. Zhong Yi Yao Xue Bao, 48(7):43-46. https://doi.org/10.19664/j.cnki.1002-2392.200124
[61] Zhang ZJ, Liu SN & Zhang YY. (2019). Experience of Jia Yusen in diagnosis and treatment of sterility. Beijing J Tradit Chin Med, 38(3), 246-249. https://doi.org/10.16025/j.1674-1307.2019.03.014
[62] Zitzmann M. (2024). Testosterone deficiency and chronic kidney disease. J Clin Transl Endocrinol, 6:100365. https://doi.org/10.1016/j.jcte.2024.100365
[63] Luo HZ. (2020). Study on the Synthesis Process and Quality of Abiraterone Acetate. [Master's thesis, Nanchang University], doi: 10.27232/d.cnki.gnchu.2020.003586.
[64] Wen YX, Zhou YC, Yang SY, Huang YP, Huang XZ & Zhao NJ. (2016). Experience of Li Peiwen in treating prostate carcinoma. China J Tradit Chin Med Pharm, 31(8), 3109-3111. https://doi.org/10.3969/j.issn.1673-1727.2016.08.040
[65] Li XJ, Feng MH, Mou RY, Guo SQ, Li WJ, Zhang C, et al. (2020). Clinical observation on treatment of androgen deficiency syndrome after endocrine therapy for advanced prostate cancer by "Jianpi Lishi Huayu Method". Chin Tradit Herb Drugs, 51(21), 5559-5565. https://doi.org/10.7501/j.issn.0253-2670.2020.21.019
[66] Liu SX, Zeng FX, Shao KQ, Shen JW, Gao Z & Li Q. (2016). The situation of treating male late-onset hypogonadism with traditional Chinese medicine. Int J Tradit Chin Med, 38(1), 85-88. https://doi.org/10.3760/cma.j.issn.1673-4246.2016.01.024
[67] Zhang QF, Zhang Y & Ding Y. (2018). Clinical research of Erxian Decoction in treating the both kidney yin and yang deficiency type of late-onset hypogonadism in males. J Nanjing Univ Tradit Chin Med, 34(3), 269-272. https://doi.org/10.14148/j.issn.1672-0482.2018.0269
[68] Niu ZH. (2023). Clinical study of Erdizishen Decoction in treating androgen deficiency syndrome caused by endocrine therapy for prostate cancer. [Master's thesis]. Kunming: Yunnan University of Traditional Chinese Medicine. https://doi.org/10.27460/d.cnki.gyzyc.2023.000090
[69] Liu B, Ding LL, Chen ZJ, Zhang GX, & Wang B. (2024). The mechanism of rhizoma drynariae and its active components in the prevention and treatment of osteoporosis. Zhongguo Gu Zhi Shu Song Za Zhi, 30(10):1540-1547. https://doi.org/10.3969/j.issn.1006-7108.2024.10.025
[70] Han JW, Li L, Zhang C, Huang QQ, Wang SL, & Li WY, et al. (2022). Eucommia, Cuscuta, and Drynaria extracts ameliorate glucocorticoid-induced osteoporosis by inhibiting osteoclastogenesis through PI3K/Akt pathway. Front Pharmacol, 13:772944. https://doi.org/10.3389/fphar.2021.772944
[71] Wen XL, Cai FY, Shan S, Liao YA, & Liu HN. (2023). Research progress on the mechanism of tumor prevention and treatment of Liuwei Dihuang Pills. Yatai Chuantong Yiyao, 19(6):223-226. https://doi.org/10.11954/ytctyy.202306047
Type
Published
Data Availability Statement
The datasets and literature supporting the findings of this study are sourced from publicly available repositories, specifically the China National Knowledge Infrastructure (CNKI) and the National Library of China. These platforms provide access to a comprehensive collection of academic articles, books, and other scholarly resources. All references cited in this manuscript can be retrieved through these sources. No additional datasets were generated or analyzed as part of this research.
Issue
Section
License
Copyright (c) 2025 Cell Conflux
This work is licensed under a Creative Commons Attribution 4.0 International License.
